SK110599A3 - A medicament against infertility and for increasing fertility - Google Patents

A medicament against infertility and for increasing fertility Download PDF

Info

Publication number: SK110599A3
Authority: SK; Slovakia
Prior art keywords: lidocaine; sperm; endometriosis; local anesthetic; infertility
Prior art date: 1997-02-15

Application number

SK1105-99A

Other languages

English (en)

Slovak (sk)

Inventor

Greta Edelstam

Original Assignee

Edelstam Inc

Greta Edelstam

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-02-15

Filing date

1998-02-09

Publication date

2000-11-07

1998-02-09 Application filed by Edelstam Inc, Greta Edelstam filed Critical Edelstam Inc

2000-11-07 Publication of SK110599A3 publication Critical patent/SK110599A3/sk

Links

208000000509 infertility Diseases 0.000 title claims abstract description 21
230000036512 infertility Effects 0.000 title claims abstract description 21
231100000535 infertility Toxicity 0.000 title claims abstract description 21
230000035558 fertility Effects 0.000 title claims abstract description 14
239000003814 drug Substances 0.000 title claims abstract description 6
238000000034 method Methods 0.000 claims abstract description 18
239000003589 local anesthetic agent Substances 0.000 claims abstract description 15
238000004519 manufacturing process Methods 0.000 claims abstract description 4
239000008194 pharmaceutical composition Substances 0.000 claims abstract 6
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 58
229960004194 lidocaine Drugs 0.000 claims description 55
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
210000003101 oviduct Anatomy 0.000 claims description 9
239000011780 sodium chloride Substances 0.000 claims description 9
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims description 8
229920002674 hyaluronan Polymers 0.000 claims description 8
229940099552 hyaluronan Drugs 0.000 claims description 8
210000000683 abdominal cavity Anatomy 0.000 claims description 5
ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims description 4
LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 4
229960003150 bupivacaine Drugs 0.000 claims description 3
229960002409 mepivacaine Drugs 0.000 claims description 3
INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims description 3
229960001807 prilocaine Drugs 0.000 claims description 3
MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 3
229960001549 ropivacaine Drugs 0.000 claims description 3
239000008177 pharmaceutical agent Substances 0.000 claims 3
230000002708 enhancing effect Effects 0.000 claims 1
230000008569 process Effects 0.000 abstract description 5
239000000546 pharmaceutical excipient Substances 0.000 abstract description 3
238000011835 investigation Methods 0.000 abstract 1
201000009273 Endometriosis Diseases 0.000 description 32
210000003567 ascitic fluid Anatomy 0.000 description 27
238000011534 incubation Methods 0.000 description 25
210000004027 cell Anatomy 0.000 description 22
210000000265 leukocyte Anatomy 0.000 description 21
238000011282 treatment Methods 0.000 description 18
230000003187 abdominal effect Effects 0.000 description 16
239000012530 fluid Substances 0.000 description 16
230000000694 effects Effects 0.000 description 14
230000000750 progressive effect Effects 0.000 description 11
230000004083 survival effect Effects 0.000 description 11
150000001875 compounds Chemical class 0.000 description 10
230000016087 ovulation Effects 0.000 description 10
238000003744 In vitro fertilisation Methods 0.000 description 8
230000004720 fertilization Effects 0.000 description 8
231100000502 fertility decrease Toxicity 0.000 description 7
206010057249 Phagocytosis Diseases 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 6
230000008782 phagocytosis Effects 0.000 description 6
239000004809 Teflon Substances 0.000 description 5
229920006362 Teflon® Polymers 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
230000004054 inflammatory process Effects 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 4
102000009151 Luteinizing Hormone Human genes 0.000 description 4
108010073521 Luteinizing Hormone Proteins 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
235000013601 eggs Nutrition 0.000 description 4
210000003024 peritoneal macrophage Anatomy 0.000 description 4
230000035935 pregnancy Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
230000019100 sperm motility Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
102000002322 Egg Proteins Human genes 0.000 description 3
108010000912 Egg Proteins Proteins 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000002411 adverse Effects 0.000 description 3
239000011521 glass Substances 0.000 description 3
238000002357 laparoscopic surgery Methods 0.000 description 3
229940040129 luteinizing hormone Drugs 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
230000027758 ovulation cycle Effects 0.000 description 3
210000004681 ovum Anatomy 0.000 description 3
208000012404 paroxysmal familial ventricular fibrillation Diseases 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
230000035899 viability Effects 0.000 description 3
208000004998 Abdominal Pain Diseases 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010067482 No adverse event Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
102100036154 Platelet basic protein Human genes 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
230000003444 anaesthetic effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
210000001109 blastomere Anatomy 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000000337 buffer salt Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000835 fiber Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
208000021267 infertility disease Diseases 0.000 description 2
230000004899 motility Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
206010002659 Anovulatory cycle Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102000003896 Myeloperoxidases Human genes 0.000 description 1
108090000235 Myeloperoxidases Proteins 0.000 description 1
241000337007 Oceania Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
238000004820 blood count Methods 0.000 description 1
238000009534 blood test Methods 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
229960003608 clomifene Drugs 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000000687 effect on sperms Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000008175 fetal development Effects 0.000 description 1
210000001733 follicular fluid Anatomy 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229940088592 immunologic factor Drugs 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
229940071308 lidocaine 10 mg/ml Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000002690 local anesthesia Methods 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
231100000862 numbness Toxicity 0.000 description 1
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
229940052264 other local anesthetics in atc Drugs 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000004526 pharmaceutical effect Effects 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
-1 polypropylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000000047 product Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000003307 reticuloendothelial effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
239000011345 viscous material Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Pain & Pain Management (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Medicinal Preparation (AREA)

SK1105-99A 1997-02-15 1998-02-09 A medicament against infertility and for increasing fertility SK110599A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/800,737 US5977143A (en)	1997-02-15	1997-02-15	Medicament against infertility which reduces phagocytosis of spermatozoa in women
PCT/US1998/002267 WO1998035676A1 (en)	1997-02-15	1998-02-09	A medicament against infertility and for increasing fertility

Publications (1)

Publication Number	Publication Date
SK110599A3 true SK110599A3 (en)	2000-11-07

Family

ID=25179227

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1105-99A SK110599A3 (en)	1997-02-15	1998-02-09	A medicament against infertility and for increasing fertility

Country Status (23)

Country	Link
US (1)	US5977143A (de)
EP (1)	EP1001771B1 (de)
JP (1)	JP3497513B2 (de)
KR (1)	KR20000071053A (de)
CN (1)	CN1248915A (de)
AT (1)	ATE295169T1 (de)
AU (1)	AU743346B2 (de)
BR (1)	BR9807370A (de)
CA (1)	CA2280685C (de)
DE (1)	DE69830176T2 (de)
EE (1)	EE9900346A (de)
ES (1)	ES2245022T3 (de)
HU (1)	HUP0001342A3 (de)
IL (1)	IL131267A0 (de)
IS (1)	IS5152A (de)
LT (1)	LT4661B (de)
LV (1)	LV12450B (de)
NO (1)	NO321663B1 (de)
NZ (1)	NZ337504A (de)
PL (1)	PL335419A1 (de)
SK (1)	SK110599A3 (de)
TR (1)	TR199901958T2 (de)
WO (1)	WO1998035676A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000053183A1 (en) *	1997-02-15	2000-09-14	Edelstam Inc.	Medicament against dysmenorrhoea and premenstrual syndrome
US8425892B2 (en)	2001-10-29	2013-04-23	Columbia Laboratories, Inc.	Extended, controlled-release pharmaceutical compositions using charged polymers
US20030114394A1 (en) *	2001-10-29	2003-06-19	Levine Howard L.	Vaginally administered anti-dysrhythmic agents for treating pelvic pain
WO2011145993A1 (en) *	2010-05-19	2011-11-24	Isifer Ab	Treatment for reducing inflammation
US11191839B2 (en) *	2015-10-23	2021-12-07	Isifer Ab	Composition for treatment of infertility in a female subject
KR101802090B1 (ko) *	2016-09-26	2017-11-27	서울대학교산학협력단	탈락막 자궁내막 세포를 포함하는 자궁내막 손상의 치료용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3115625B2 (ja)	1991-03-30	2000-12-11	帝國製薬株式会社	リドカイン含有外用貼付剤
FR2704147B1 (fr) *	1993-04-22	1995-07-21	Leguern Jacques	Composition régénératrice des cellules et son application en milieu médical, vétérinaire et agricole.

1997
- 1997-02-15 US US08/800,737 patent/US5977143A/en not_active Expired - Lifetime
1998
- 1998-02-09 PL PL98335419A patent/PL335419A1/xx unknown
- 1998-02-09 SK SK1105-99A patent/SK110599A3/sk unknown
- 1998-02-09 DE DE69830176T patent/DE69830176T2/de not_active Expired - Lifetime
- 1998-02-09 KR KR1019997007322A patent/KR20000071053A/ko not_active Ceased
- 1998-02-09 ES ES98904958T patent/ES2245022T3/es not_active Expired - Lifetime
- 1998-02-09 IL IL13126798A patent/IL131267A0/xx unknown
- 1998-02-09 EE EEP199900346A patent/EE9900346A/xx unknown
- 1998-02-09 CA CA002280685A patent/CA2280685C/en not_active Expired - Lifetime
- 1998-02-09 AU AU62703/98A patent/AU743346B2/en not_active Expired
- 1998-02-09 EP EP98904958A patent/EP1001771B1/de not_active Expired - Lifetime
- 1998-02-09 NZ NZ337504A patent/NZ337504A/xx not_active IP Right Cessation
- 1998-02-09 CN CN98802557A patent/CN1248915A/zh active Pending
- 1998-02-09 AT AT98904958T patent/ATE295169T1/de not_active IP Right Cessation
- 1998-02-09 JP JP53582598A patent/JP3497513B2/ja not_active Expired - Lifetime
- 1998-02-09 HU HU0001342A patent/HUP0001342A3/hu unknown
- 1998-02-09 TR TR1999/01958T patent/TR199901958T2/xx unknown
- 1998-02-09 WO PCT/US1998/002267 patent/WO1998035676A1/en not_active Ceased
- 1998-02-09 BR BR9807370-2A patent/BR9807370A/pt not_active IP Right Cessation
1999
- 1999-08-11 IS IS5152A patent/IS5152A/is unknown
- 1999-08-12 LT LT99-101A patent/LT4661B/lt not_active IP Right Cessation
- 1999-08-13 NO NO19993921A patent/NO321663B1/no not_active IP Right Cessation
- 1999-09-08 LV LVP-99-119A patent/LV12450B/en unknown

Also Published As

Publication number	Publication date
JP3497513B2 (ja)	2004-02-16
LT99101A (en)	2000-03-27
BR9807370A (pt)	2000-03-14
NO993921L (no)	1999-08-13
EP1001771A4 (de)	2000-09-27
PL335419A1 (en)	2000-04-25
CA2280685A1 (en)	1998-08-20
CN1248915A (zh)	2000-03-29
EE9900346A (et)	2000-02-15
US5977143A (en)	1999-11-02
EP1001771B1 (de)	2005-05-11
AU6270398A (en)	1998-09-08
LV12450B (en)	2000-10-20
EP1001771A1 (de)	2000-05-24
TR199901958T2 (xx)	1999-12-21
AU743346B2 (en)	2002-01-24
JP2000513737A (ja)	2000-10-17
DE69830176T2 (de)	2006-01-26
LT4661B (lt)	2000-05-25
HUP0001342A3 (en)	2000-10-30
LV12450A (lv)	2000-04-20
CA2280685C (en)	2004-06-29
NO321663B1 (no)	2006-06-19
NO993921D0 (no)	1999-08-13
ES2245022T3 (es)	2005-12-16
NZ337504A (en)	2001-01-26
IL131267A0 (en)	2001-01-28
WO1998035676A1 (en)	1998-08-20
KR20000071053A (ko)	2000-11-25
IS5152A (is)	1999-08-11
ATE295169T1 (de)	2005-05-15
HUP0001342A2 (hu)	2000-09-28
DE69830176D1 (de)	2005-06-16

Publication	Publication Date	Title
Howard et al.	1997	Sensitivity to exogenous gonadotropins for ovulation induction and laparoscopic artificial insemination in the cheetah and clouded leopard
Moraloglu et al.	2010	Treatment with oxytocin antagonists before embryo transfer may increase implantation rates after IVF
Afifi et al.	2010	Management of endometrial polyps in subfertile women: a systematic review
Liu et al.	2006	Comparing the pregnancy rates of one versus two intrauterine inseminations (IUIs) in male factor and idiopathic infertility: Liu, Gong, Luo, and Lu
CN108348527A (zh)	2018-07-31	用于治疗癫痫的方法
SK110599A3 (en)	2000-11-07	A medicament against infertility and for increasing fertility
CN1642540B (zh)	2014-12-10	作为局部杀微生物药和避孕药的苏拉明及其衍生物
AU774046B2 (en)	2004-06-17	Medicament against dysmenorrhoea and premenstrual syndrome
Liffner et al.	2024	Intravaginal exposure to seminal plasma after ovum pick-up does not increase live birth rates after in vitro fertilization or intracytoplasmic sperm injection treatment: a double-blind, placebo-controlled randomized trial
WO2010036878A1 (en)	2010-04-01	Use of trpv1 receptor agonists in cervical pain and labor
CZ280699A3 (cs)	2000-01-12	Lék proti neplodnosti a ke zvýšení plodnosti
Kjærgaard et al.	1988	Prazosin, an adrenergic blocking agent inadequate as male contraceptive pill
Yu Ng et al.	2003	A randomized double-blind study to compare the effectiveness of three different doses of lignocaine used in paracervical block during oocyte retrieval
MXPA99007534A (en)	2001-12-04	A medicament against infertility and for increasing fertility
HK1025054A (en)	2000-11-03	A medicament against infertility and for increasing fertility
JP2018535253A (ja)	2018-11-29	女性対象における不妊症の治療ための組成物
Lucchini et al.	2012	Comparison of intrafollicular sperm injection and intrauterine insemination in the treatment of subfertility
KR20250162796A (ko)	2025-11-19	보호용 생체반응성 중합체 씰
Hassan et al.	2020	Twenty four hours sperm survival test after sperms preparation with and without Pentoxifylline adding
WO2001080861A1 (en)	2001-11-01	Infertility or increasing fertility